ESMO Young Oncologist Journal Club

The ESMO Young Oncologists Committee is proud to host the Young Oncologist Journal Club. On a regular basis (1-3 times a month), a committee member – or a specially invited young oncologists – provides you with an appraisal of an important clinical and/or translational article published in a major journal. The appraisers add their comments analysing the clinical relevance of the article and possible considerations.

Get involved by reading the review, share your thoughts and raise questions for discussion by logging in and commenting on the article. Commenting is reserved to ESMO Members only. We look forward to your input!

Submit an article


Topic Title Author
Central nervous system malignancies Bevacizumab-Induced Tumour Calcifications as a Surrogate Marker of Outcome in Patients with Glioblastoma Matthias Preusser
Lung and other thoracic tumours Randomised Phase II Study of Erlotinib plus Tivantinib versus Erlotinib plus Placebo in Pretreated NSCLC Patients: have we found a KRAS targeting agent? Giulio Metro
Genitourinary cancers Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants David Olmos
Haematologic malignancies Maintenance Therapy with Rituximab Prolongs the Progression-Free Survival in Follicular Lymphoma. Results from the PRIMA trial Sari Riihijarvi
Gastrointestinal cancers Adjuvant chemotherapy for stage II colon cancer with poor prognostic features: the controversy is still open Erika Martinelli
Gastrointestinal cancers A step forward in pancreatic ductal adenocarcinoma gene expression classification: Subtypes linked to survival and drug sensibility Alessandro Leal
Gynaecologic malignancies Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) Susana Banerjee
Head and neck cancers Gene expression profiling predicts the development of oral cancer Gilberto de Castro
Genitourinary cancers New treatment in prostate cancer: Abiraterone and the beginning of a new era in prostate cancer Christophe Massard
Lung and other thoracic tumours Combined EGFR / MET targeting in lung cancer therapeutics – the transition from preclinical evidence to clinical data Michalis V. Karamouzis
Melanoma BRAF selective inhibitors in advanced melanoma. The revolution has begun Raffaele Califano
Gynaecologic malignancies Cost-effectiveness of bevacizumab in the management of ovarian cancer: too high the costs, or too low the benefits? Valentina Guarneri
Breast cancer Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomised clinical trial. Alessandro Leal; Evandro de Azambuja
Gastrointestinal cancers KRAS Mutation Analysis: A Comparison Between Primary Tumours and Matched Liver Metastases in 305 Colorectal Cancer Patients Konstantinos Kamposioras